Skip to main content

Beam Therapeutics Inc. (BEAM)

NASDAQ: BEAM · Delayed Price · USD
95.50
+0.53 (0.56%)
Pre-market:Oct 22, 2021 8:00 AM EDT
94.97
0.86 (0.91%)
At close: Oct 21, 4:00 PM
Market Cap6.33B
Revenue (ttm)24,000
Net Income (ttm)-407.73M
Shares Out62.21M
EPS (ttm)-7.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume324,677
Open94.65
Previous Close94.11
Day's Range94.20 - 97.50
52-Week Range32.97 - 138.52
Betan/a
AnalystsBuy
Price Target127.13 (+33.9%)
Est. Earnings DateNov 9, 2021

About BEAM

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies...

IndustryBeverages
IPO DateFeb 6, 2020
Employees266
Stock ExchangeNASDAQ
Ticker SymbolBEAM
Full Company Profile

Financial Performance

In 2020, BEAM's revenue was $24,000, an increase of 33.33% compared to the previous year's $18,000. Losses were -$194.59 million, 148.4% more than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is 127.13, which is an increase of 33.86% from the latest price.

Price Target
$127.13
(33.86% upside)
Analyst Consensus: Buy

News

If I Could Only Own 1 Healthcare Stock, This Is What It Would Be

Investing gets simple if you have to put all of your eggs in one basket.

23 hours ago - The Motley Fool

Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John ...

2 days ago - GlobeNewsWire

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology

Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy prog...

2 days ago - Benzinga

Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease...

Findings Show Base Editing Leads to Elimination of Disease Phenotype in an In Vivo Model Findings Show Base Editing Leads to Elimination of Disease Phenotype in an In Vivo Model

3 days ago - GlobeNewsWire

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Other symbols:ALLONTLA
6 days ago - The Motley Fool

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.

Other symbols:CRSPEDITSRPT
1 week ago - Zacks Investment Research

Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought

All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.

Other symbols:DNASGFY
1 week ago - The Motley Fool

Got $500? 3 Game-Changing Stocks to Buy Right Now

The disruptive potential for these companies is huge.

Other symbols:FBMTTR
2 weeks ago - The Motley Fool

Step Aside, Genomic Revolution. Welcome, the Proteomic Revolution!

Just as next-gen sequencing (NGS) tech kickstarted a multi-hundred-billion-dollar Genomic Revolution that resulted in multiple 10X winners in the 2010s, next-gen protein sequencing (NGPS) tech will kick...

2 weeks ago - InvestorPlace

Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeti...

CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the c...

3 weeks ago - GlobeNewsWire

Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...

3 weeks ago - GlobeNewsWire

Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection

Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce viral markers, including hepatitis B surfac...

3 weeks ago - Benzinga

Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chro...

Data to be Presented During an Oral Presentation at the 2021 International HBV Meeting Data to be Presented During an Oral Presentation at the 2021 International HBV Meeting

3 weeks ago - GlobeNewsWire

Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies

Beam Therapeutics Inc (NASDAQ: BEAM) has announced new preclinical data for novel lipid nanoparticle (LNP) formulations for in vivo liver editing.  The Company says that continued optimization of LNPs h...

4 weeks ago - Benzinga

Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base ...

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new precl...

4 weeks ago - GlobeNewsWire

Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another

Wood is following an important strategy with gene-editing stocks.

Other symbols:CRSPEDITVRTX
4 weeks ago - The Motley Fool

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared fi...

1 month ago - InvestorPlace

Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy?

One biotech could have the inside track to profit from a major achievement in CRISPR gene editing.

1 month ago - The Motley Fool

Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...

1 month ago - GlobeNewsWire

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic Rev...

Other symbols:EDITILMNNTLA
1 month ago - InvestorPlace

The 3 Best Biotech Stocks to Buy Right Now

Let your portfolio reflect your personality.

Other symbols:ALXOVRTX
1 month ago - The Motley Fool

3 Stocks to Avoid if Cathie Wood's ARK ETF Falls

They likely to do the worst if Michael Burry is right.

Other symbols:COINTSLA
2 months ago - The Motley Fool

How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

2 months ago - Zacks Investment Research

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -63.79% and -99.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results

Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021

2 months ago - GlobeNewsWire